title: Alteration of splice site selection in the LMNA gene and inhibition of progerin production via AMPK activation.
abstract: Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic condition characterized by an accelerated aging phenotype and an average life span of 13years. Patients typically exhibit extensive pathophysiological vascular alterations, eventually resulting in death from stroke or myocardial infarction. A silent point mutation at position 1824 (C1824T) of the LMNA gene, generating a truncated form of lamin A (progerin), has been shown to be the cause of most cases of HGPS. Interestingly, this mutation induces the use of an internal 5' cryptic splice site within exon 11 of the LMNA pre-mRNA, leading to the generation of progerin via aberrant alternative splicing. The serine-arginine rich splicing factor 1 (SRSF1 or ASF/SF2) has been shown to function as an oncoprotein and is upregulated in many cancers and other age-related disorders. Indeed, SRSF1 inhibition results in a splicing ratio in the LMNA pre-mRNA favoring lamin A production over that of progerin. It is our hypothesis that activation of AMP-activated protein kinase (AMPK), a master regulator of cellular metabolism, may lead to a reduction in SRSF1 and thus a decrease in the use of the LMNA 5' cryptic splice site in exon 11 through upregulation of p32, a splicing factor-associated protein and putative mitochondrial chaperone that has been shown to inhibit SRSF1 and enhance mitochondrial DNA (mtDNA) replication and oxidative phosphorylation. AMPK activation by currently available compounds such as metformin, resveratrol, and berberine may thus have wide-ranging implications for disorders associated with increased production and accumulation of progerin.
authors.affiliation: Finley BioSciences, Houston, TX 77042-4539, United States. Electronic address: jfinley4@johnshopkins.edu.
authors.forename: Jahahreeh
authors.initials: J
authors.lastname: Finley
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D017398:Alternative Splicing; D000818:Animals; D001599:Berberine / Q000627:therapeutic use; D004272:DNA, Mitochondrial / Q000378:metabolism; D004789:Enzyme Activation; D005091:Exons; D005786:Gene Expression Regulation; D006801:Humans; D034904:Lamin Type A / Q000235:genetics* / Q000378:metabolism*; D008687:Metformin / Q000627:therapeutic use; D008954:Models, Biological; D009154:Mutation; D009687:Nuclear Proteins / Q000378:metabolism; D010085:Oxidative Phosphorylation; D010766:Phosphorylation; D017354:Point Mutation; D011371:Progeria / Q000235:genetics / Q000503:physiopathology; D016601:RNA-Binding Proteins / Q000378:metabolism; D000077185:Resveratrol; D000068103:Serine-Arginine Splicing Factors; D013267:Stilbenes / Q000627:therapeutic use
chemical_list: D004272:DNA, Mitochondrial; C494847:LMNA protein, human; D034904:Lamin Type A; D009687:Nuclear Proteins; D016601:RNA-Binding Proteins; D013267:Stilbenes; C090764:prelamin A; D001599:Berberine; D000068103:Serine-Arginine Splicing Factors; D008687:Metformin; D055372:AMP-Activated Protein Kinases; D000077185:Resveratrol